Loading…
Congressional Budget Justification Transparency Act of 2021
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
59pct
2d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Congressional Budget Justification Transparency Act of 2021 This bill requires federal agencies to post budget justification materials on certain public websites, including a single searchable website (e.g., USAspending.gov) and each agency's website. The materials most be posted in an open format that enables users to download individual reports, all reports in bulk, and the results of a search. In addition, the materials must be posted no later than two weeks after they are first submitted to Congress. The bill also requires the Office of Management and Budget to maintain a public website that includes details regarding the materials, including a list of the agencies that submit budget justification materials to Congress, the dates that the materials were submitted to Congress and posted online, and links to the materials.
Yes
412
No
2
Present
0
Not Voting
16
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2022 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Inflation Reduction Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 2 (Roll no. 9). (text: CR H62)
HousePassed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 412 - 2 (Roll no. 9).(text: CR H62)
HouseConsidered as unfinished business. (consideration: CR H71-72)
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
DEBATE - The House proceeded with forty minutes of debate on H.R. 22.
Considered under suspension of the rules. (consideration: CR H62-66)
Mrs. Maloney, Carolyn B. moved to suspend the rules and pass the bill.
Bills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| house |
| On Motion to Suspend the Rules and Pass |
Passed |
| January 5, 2021 |
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Inflation Reduction Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Inflation Reduction Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Inflation Reduction Act. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R. 6833, making continuing appropriations for fiscal year 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act and H.R.6833 - Making continuing appropriations for fiscal year 2023, and for other purposes. H.R.6833 - Making continuing appropriations for fiscal year 2023.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res.14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res.14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. H.R.2471, Consolidated Appropriations Act, issues related to 340B and ESRD.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Budget/Appropriations
- House and Senate Legislative Branch Appropriations Bill, FY 2022 (HR 4346), Pro-transparency provisions & strengthening congress - House and Senate CJS Appropriations Bill, FY 2022 (HR 4505), Public access to OLC opinions, FARA Reform - House and Senate FSGG Appropriations Bill, FY 2022 (HR 4345), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs - House and Senate Defense Appropriations Bill, FY 2022 (4432), FISC Opinion transparency - Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications - Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters - Unnamed Appropriations Omnibus for FY 2022; Pro-transparency provisions & strengthening congress - Various unnamed appropriations bills for FY 2023; Pro-transparency provisions & strengthening congress
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Budget/Appropriations
- House and Senate Legislative Branch Appropriations Bill, FY 2022 (HR 4346), Pro-transparency provisions & strengthening congress - House and Senate CJS Appropriations Bill, FY 2022 (HR 4505), Public access to OLC opinions, FARA Reform - House and Senate FSGG Appropriations Bill, FY 2022 (HR 4345), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs - House and Senate Defense Appropriations Bill, FY 2022 (4432), FISC Opinion transparency - Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications - Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters - Unnamed Appropriations Omnibus for FY 2022; Pro-transparency provisions & strengthening congress - Various unnamed appropriations bills for FY 2023; Pro-transparency provisions & strengthening congress
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · fourth_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Budget/Appropriations
- House and Senate Legislative Branch Appropriations Bill, FY 2022 (HR 4346), Pro-transparency provisions & strengthening congress - House and Senate CJS Appropriations Bill, FY 2022 (HR 4505), Public access to OLC opinions, FARA Reform - House and Senate FSGG Appropriations Bill, FY 2022 (HR 4345), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs - House and Senate Defense Appropriations Bill, FY 2022 (4432), FISC Opinion transparency - Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications - Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters
Client expense: $360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Budget/Appropriations
-House and Senate Legislative Branch Appropriations Bill, FY 2022 (HR 4346), Pro-transparency provisions & strengthening Congress -House and Senate CJS Appropriations Bill, FY 2022 (4505), Public access to OLC opinions, FARA Reform -House and Senate FSGG Appropriations Bill, FY 2022 (4345), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs -House and Senate Defense Appropriations Bill, FY 2021 (HR 4432), FISC Opinion transparency -Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications -Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters
Client expense: $430,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Budget/Appropriations
Transportation, Housing and Urban Development Act of 2022, level authorized by HR 22 extension Transportation, Housing and Urban Development Act of 2022, supplemental funding for aviation infrastructure grants Transportation, Housing and Urban Development Act of 2022, increased funding for Carl D. Perkins Career and Technical Education Act State Grants
Client expense: $114,571 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Federal Aviation Administration (FAA), Federal Highway Administration (FHA), Federal Motor Carrier Safety Administration, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Occupational Safety & Health Administration (OSHA), SENATE, Transportation, Dept of (DOT)
2021 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · third_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Government Issues
Whistleblower protections Transparency in OMB apportionment decisions H.R. 336TRUST in Congress Act House Whistleblower Ombudsman Office H.R. 2988Whistleblower Protection Improvement Act H.R. 1224Merit Systems Protection Board Empowerment Act H.R. 6628, S. 3889Congressional Power of the Purse Act (116th Congress) H.R. 8294National Apprenticeship Act H.R. 8363, S. 4880Protecting Our Democracy Act (116th Congress) S. 241, H.R. 1755ARTICLE ONE Act Antideficiency Act and Impoundment Control Act reform H.R. 22, S. 272Congressional Budget Justification Transparency Act of 2021 H.R. 638Cost Estimates Improvement Act H.R. 846, S. 268COVID-19 Whistleblower Protection Act H.R. 1, S. 1For the People Act S. 693, H.R. 3327No Congressionally-Obligated Recurring Revenue Used as Pensions To Incarcerated Officials Now (No CORRUPTION) Act S. 583Promoting Rigorous and Innovative Cost Efficiencies for Federal Procurement and Acquisitions (PRICE) Act of 2021 S. 636Billion Dollar Boondoggle Act of 2021 S. 522Providing Accountability Through Transparency Act of 2021. S. 667Duplication Scoring Act of 2021 H.R. 2043Periodically Listing Updates to Management (PLUM) Act Funding for federal buildings in the American Jobs Plan H.R. 2994Accountability for Acting Officials Act S. 68, H.R. 1776Regulations from the Executive in Need of Scrutiny Act of 2021 S. 628, H.R. 1605Guidance Out Of Darkness Act S. 969, H.R. 2251Coronavirus Regulatory Repeal Act of 2021 S. 533, H.R. 1508Guidance Clarity Act of 2021 S. 587Securing Inspector General Independence Act of 2021 H.R. 2662Inspector General Independence and Empowerment Act H.R. 3494Separation of Powers Restoration Act of 2021 S. 2239Unnecessary Agency Regulations Reduction Act Executive Orders 13891 & 13892Promoting transparency in guidance
Client expense: $30,000 · Firm income: Not reported
2021 · second_quarter · Budget/Appropriations
Transportation, Housing and Urban Development Act of 2022, level authorized by HR 22 extension Transportation, Housing and Urban Development Act of 2022, supplemental funding for aviation infrastructure grants Transportation, Housing and Urban Development Act of 2022, increased funding for Carl D. Perkins Career and Technical Education Act State Grants
Client expense: $110,154 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Federal Aviation Administration (FAA), Federal Highway Administration (FHA), Federal Motor Carrier Safety Administration, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Occupational Safety & Health Administration (OSHA), SENATE, Transportation, Dept of (DOT)
2021 · second_quarter · Budget/Appropriations
- House and Senate Legislative Branch Appropriations Bill, FY 2022 (HR 4346), Pro-transparency provisions & strengthening congress - House and Senate CJS Appropriations Bill, FY 2022 (unnamed), Public access to OLC opinions, FARA Reform - House and Senate FSGG Appropriations Bill, FY 2022 (HR 4345), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs - House and Senate Defense Appropriations Bill, FY 2022 (unnamed), FISC Opinion transparency - Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications - Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters - Budget resolution (H. Con. Res. 11, S.Con.Res 5), Concerning funding for the legislative branch
Client expense: $1,110,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Budget/Appropriations
-House and Senate Legislative Branch Appropriations Bill, FY 2022 (unnamed), Pro-transparency provisions & strengthening Congress -House and Senate CJS Appropriations Bill, FY 2022 (unnamed), Public access to OLC opinions, FARA Reform -House and Senate FSGG Appropriations Bill, FY 2022 (unnamed), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs -House and Senate Defense Appropriations Bill, FY 2021 (HR 7617), FISC Opinion transparency -Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications -Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters -Budget resolution (H. Con. Res. 11, S.Con.Res 5), Concerning funding for the legislative branch
Client expense: $460,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to the CY 2022 ESRD PPS Proposed Rule.
Client expense: Not reported · Firm income: $60,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $40,000
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2021 · second_quarter · Pharmacy
Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act. Issues related to supply chains, 340B, and the COVID-19 pandemic.
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Government Issues
H.R. 3830, S. 2177Taxpayers Right-to-Know Act Whistleblower protections Reform and increased support to Inspectors General and the Government Accountability Office Transparency in OMB apportionment decisions H.R. 336TRUST in Congress Act House Whistleblower Ombudsman Office S. 3332/H.R. 5980NO CORRUPTION Act H.R. 7929/H.R. 8038Pandemic Preparedness, Response, and Recovery Act H.R. 7935Whistleblower Protection Improvement Act H.R. 7864Merit Systems Protection Board Empowerment Act H.R. 8235Open Courts Act H.R. 6628, S. 3889Congressional Power of the Purse Act H.R. 8294National Apprenticeship Act H.R. 8363, S. 4880Protecting Our Democracy Act S. 241ARTICLE ONE Act S. 938A bill to require the President to declare a national emergency relating to climate change under the National Emergencies Act, and for other purposes. Antideficieny Act and Impoundment Control Act reform H.R. 22, S. 272Congressional Budget Justification Transparency Act of 2021 H.R. 638Cost Estimates Improvement Act H.R. 846, S. 268COVID-19 Whistleblower Protection Act H.R. 2251To establish Federal Regulatory Review Commissions, and for other purposes. H.R. 1937, S. 760COST Act H.R. 2199, S. 925Federal Agency Sunset Commission Act of 2021 H. Res. 263Finding Federal Savings Committee Resolution HR 1For the people act S. 628Guidance Out of Darkness Act S 693No Congressionally-Obligated Recurring Revenue Used as Pensions To Incarcerated Officials Now (No CORRUPTION) Act S. 583 Promoting Rigorous and Innovative Cost Efficiencies for Federal Procurement and Acquisitions (PRICE) Act of 2021 S. 636Billion Dollar Boondoggle Act of 2021 S. 522Providing Accountability Through Transparency Act of 2021. S. 667Duplication Scoring Act of 2021 Periodically Listing Updates to Management (PLUM) Act
Client expense: $30,000 · Firm income: Not reported
2021 · first_quarter · Budget/Appropriations
Transportation, Housing and Urban Development Act of 2021, level authorized by HR 22 extension Transportation, Housing and Urban Development Act of 2021, supplemental funding for aviation infrastructure grants Transportation, Housing and Urban Development Act of 2021, increased funding for Carl D. Perkins Career and Technical Education Act State Grants
Client expense: $145,305 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Federal Aviation Administration (FAA), Federal Highway Administration (FHA), Federal Motor Carrier Safety Administration, HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Occupational Safety & Health Administration (OSHA), SENATE, Transportation, Dept of (DOT)
2021 · first_quarter · Budget/Appropriations
-House and Senate Legislative Branch Appropriations Bill, FY 2022 (unnamed), Pro-transparency provisions & strengthening congress -House and Senate CJS Appropriations Bill, FY 2022 (unnamed), Public access to OLC opinions, FARA Reform -House and Senate FSGG Appropriations Bill, FY 2022 (unnamed), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs -House and Senate Defense Appropriations Bill, FY 2021 (HR 7617), FISC Opinion transparency -Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications -Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters -Budget resolution (H. Con. Res. 11, S.Con.Res 5), Concerning funding for the legislative branch
Client expense: $100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2021 · first_quarter · Budget/Appropriations
-HR 1319, American Rescue Plan - House and Senate Legislative Branch Appropriations Bill, FY 2022 (unnamed), Pro-transparency provisions & strengthening congress - House and Senate CJS Appropriations Bill, FY 2022 (unnamed), Public access to OLC opinions, FARA Reform - House and Senate FSGG Appropriations Bill, FY 2022 (unnamed), Public Access to Congressional Budget Justifications, Open Courts, Visitor Logs - House and Senate Defense Appropriations Bill, FY 2021 (HR 7617), FISC Opinion transparency - Congressional Budget Justification Transparency Act of 2021 (HR 22, S 272), Transparency around Congressional Budget Justifications - Congressional Power of the Purse Act (not yet reintroduced), Support strengthening Congressional Control + Oversight of Budgetary Matters - Budget resolution (H. Con. Res. 11, S.Con.Res 5), Concerning funding for the legislative branch
Client expense: $190,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Referred to the Committee on Oversight and Reform, and in addition to the Committee on the Budget, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| Democratic |
| DC |
| James Comer | Republican | KY |
| Jim Cooper | Democratic | TN |
| Ro Khanna | Democratic | CA |
Government targets: Defense, Dept of (DOD), Environmental Protection Agency (EPA), Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Federal Communications Commission (FCC), Federal Housing Finance Agency (FHFA), Federal Trade Commission (FTC), General Services Administration (GSA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), Postal Regulatory Commission, SENATE, Treasury, Dept of, White House Office